evorpacept + azacitidine
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Higher Risk Myelodysplastic Syndromes
Conditions
Higher Risk Myelodysplastic Syndromes
Trial Timeline
Oct 2, 2020 → Jun 10, 2025
NCT ID
NCT04417517About evorpacept + azacitidine
evorpacept + azacitidine is a phase 1 stage product being developed by ALX Oncology for Higher Risk Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT04417517. Target conditions include Higher Risk Myelodysplastic Syndromes.
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04417517 | Phase 1 | Terminated |
Competing Products
2 competing products in Higher Risk Myelodysplastic Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AMG 176 + Azacitidine | Amgen | Phase 1 | 21 |
| AK117 + Placebo + Azacitidine | Akeso | Phase 2 | 42 |